Q2
BSEM — Q2 2026 Financial Report Analysis
Medicare's flat skin-substitute rate cut BioStem's physician-office sales 90%; acquired hospital lines lifted revenue to $7.9M (-28% YoY), but a $9.0M loss, $7.0M of cash and an unpaid $10M acquisition payment brought a going-concern warning.